JP2022540773A - 弱毒化デングウイルス - Google Patents

弱毒化デングウイルス Download PDF

Info

Publication number
JP2022540773A
JP2022540773A JP2021576889A JP2021576889A JP2022540773A JP 2022540773 A JP2022540773 A JP 2022540773A JP 2021576889 A JP2021576889 A JP 2021576889A JP 2021576889 A JP2021576889 A JP 2021576889A JP 2022540773 A JP2022540773 A JP 2022540773A
Authority
JP
Japan
Prior art keywords
protein
dengue virus
less
coding sequence
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021576889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540773A5 (https=
Inventor
ステッフェン ミューラー
ジョン ロバート コールマン
チャールズ スタウフト
イン ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coda Genix Inc
Original Assignee
Coda Genix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Genix Inc filed Critical Coda Genix Inc
Publication of JP2022540773A publication Critical patent/JP2022540773A/ja
Publication of JP2022540773A5 publication Critical patent/JP2022540773A5/ja
Priority to JP2024227640A priority Critical patent/JP2025041836A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2021576889A 2019-06-25 2020-06-23 弱毒化デングウイルス Pending JP2022540773A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024227640A JP2025041836A (ja) 2019-06-25 2024-12-24 弱毒化デングウイルス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962866477P 2019-06-25 2019-06-25
US62/866,477 2019-06-25
PCT/US2020/039166 WO2020263850A1 (en) 2019-06-25 2020-06-23 Attenuated dengue viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024227640A Division JP2025041836A (ja) 2019-06-25 2024-12-24 弱毒化デングウイルス

Publications (2)

Publication Number Publication Date
JP2022540773A true JP2022540773A (ja) 2022-09-20
JP2022540773A5 JP2022540773A5 (https=) 2023-03-22

Family

ID=74060347

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576889A Pending JP2022540773A (ja) 2019-06-25 2020-06-23 弱毒化デングウイルス
JP2024227640A Pending JP2025041836A (ja) 2019-06-25 2024-12-24 弱毒化デングウイルス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024227640A Pending JP2025041836A (ja) 2019-06-25 2024-12-24 弱毒化デングウイルス

Country Status (16)

Country Link
US (1) US20220347285A1 (https=)
EP (2) EP3990014A4 (https=)
JP (2) JP2022540773A (https=)
CN (1) CN114302738A (https=)
AU (1) AU2020307532A1 (https=)
BR (1) BR112021026201A8 (https=)
CA (1) CA3145401A1 (https=)
CL (1) CL2021003475A1 (https=)
CO (1) CO2021017772A2 (https=)
CR (1) CR20210677A (https=)
DO (1) DOP2021000271A (https=)
IL (1) IL289274A (https=)
MX (1) MX2022000038A (https=)
PE (1) PE20220296A1 (https=)
PH (1) PH12021553305A1 (https=)
WO (1) WO2020263850A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
CN119899808A (zh) * 2024-12-05 2025-04-29 深圳湾实验室 登革减毒株及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118530A1 (en) * 2004-10-08 2008-05-22 Kew Olen M Modulation of Replicative Fitness By Deoptimization of Synonymous Codons
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
US20180273911A1 (en) * 2015-09-30 2018-09-27 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved rna structure
US20190002837A1 (en) * 2014-09-05 2019-01-03 The Research Foundation For The State University Of New York Recoded arbovirus and vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101621100B1 (ko) 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
US20120269849A1 (en) 2009-10-09 2012-10-25 Eckard Wimmer Attenuated influenza viruses and vaccines
CA3016697A1 (en) * 2016-03-11 2017-09-14 The Johns Hopkins University Live attenuated zika virus vaccine
WO2019172982A1 (en) * 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118530A1 (en) * 2004-10-08 2008-05-22 Kew Olen M Modulation of Replicative Fitness By Deoptimization of Synonymous Codons
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
US20190002837A1 (en) * 2014-09-05 2019-01-03 The Research Foundation For The State University Of New York Recoded arbovirus and vaccines
US20180273911A1 (en) * 2015-09-30 2018-09-27 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved rna structure

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PNAS, vol. 112, no. 15, JPN6024006230, 2015, pages 4749 - 4754, ISSN: 0005263467 *
PNAS, vol. 112, no. 28, JPN6024006228, 2015, pages 3633 - 3634, ISSN: 0005263469 *
SCIENCE, vol. 320, JPN6024006229, 2008, pages 1784 - 1787, ISSN: 0005263468 *
SCIENCE, vol. 320, no. 5884, JPN6025015570, 2008, pages 1784 - 1787, ISSN: 0005574158 *

Also Published As

Publication number Publication date
PH12021553305A1 (en) 2022-08-01
CL2021003475A1 (es) 2023-01-06
IL289274A (en) 2022-02-01
CR20210677A (es) 2022-04-26
MX2022000038A (es) 2022-02-24
WO2020263850A1 (en) 2020-12-30
EP3990014A1 (en) 2022-05-04
CA3145401A1 (en) 2020-12-30
BR112021026201A8 (pt) 2022-05-10
BR112021026201A2 (pt) 2022-02-15
CO2021017772A2 (es) 2022-04-19
CN114302738A (zh) 2022-04-08
US20220347285A1 (en) 2022-11-03
DOP2021000271A (es) 2022-04-18
JP2025041836A (ja) 2025-03-26
AU2020307532A1 (en) 2022-01-27
PE20220296A1 (es) 2022-03-07
EP4707387A2 (en) 2026-03-11
EP3990014A4 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
US20250235522A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
JP7050031B2 (ja) ワクチンにおけるデングウイルスキメラおよび組成物
Alkan et al. Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates
US12168049B2 (en) Attenuated flaviviruses
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
Pratt et al. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models
Fleeton et al. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine
Tretyakova et al. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice
JP2025041836A (ja) 弱毒化デングウイルス
Murakami et al. Development of a novel, single-cycle replicable rift valley Fever vaccine
WO2018060771A1 (en) Live attenuated chimeric zika virus and its use as an immunogenic composition
BR112017004452B1 (pt) Vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado
TW201333196A (zh) 新穎減毒小兒麻痺病毒：ｐｖ－１單－ｃｒｅ－ｘ
Zhang et al. Long-term passage of duck Tembusu virus in BHK-21 cells generates a completely attenuated and immunogenic population with increased genetic diversity
AU2019362276A1 (en) Virus vaccine
CA3022392C (en) Reoviridae vaccine
IL262510B2 (en) Robirida vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230313

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225